Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUSTIN MANSFIELD

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1699707059
CMS profile
1264732
Location
OGDEN, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,553.03

169 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,273.04 167
Consulting Fee $1,200.00 1
Education $79.99 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUSTIN MANSFIELD

NPI 1699707059 · CMS profile ID 1264732

Allopathic & Osteopathic Physicians / Internal Medicine

OGDEN, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699707059?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUSTIN MANSFIELD, NPI 1699707059, CMS profile ID 1264732. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699707059?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JUSTIN MANSFIELD, NPI 1699707059, CMS profile ID 1264732. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699707059?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JUSTIN MANSFIELD, NPI 1699707059, CMS profile ID 1264732, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 169 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1699707059?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

169 matching records · $3,553.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 169 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 169.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Nestle HealthCare Nutrition Inc. $19.5005/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820925839 CMS
VistaPharm, Inc. $14.4305/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837694169 CMS
AbbVie Inc. $7.2505/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795486799 CMS
Biogen, Inc. $12.8005/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827773939 CMS
Novo Nordisk Inc $1.8205/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810989215 CMS
Novo Nordisk Inc $12.6805/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811624619 CMS
Daiichi Sankyo Inc. $23.0205/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836291945 CMS
AbbVie Inc. $16.6305/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795486793 CMS
Amgen Inc. $24.5805/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825486865 CMS
Merck Sharp & Dohme Corporation $12.3105/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848679861 CMS
Amgen Inc. $15.7105/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825486853 CMS
Novartis Pharmaceuticals Corporation $17.0405/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813054111 CMS
Novo Nordisk Inc $8.9405/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810667763 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.5805/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820066157 CMS
Nestle HealthCare Nutrition Inc. $18.4104/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820925835 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $0.5604/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849942775 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.6104/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850202671 CMS
AbbVie Inc. $5.0104/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795486775 CMS
AbbVie Inc. $12.8304/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795486781 CMS
AbbVie Inc. $9.1604/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795486787 CMS
AbbVie Inc. $19.6604/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795486769 CMS
Novo Nordisk Inc $15.7504/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811624617 CMS
Astellas Pharma US Inc $18.4404/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821435943 CMS
Novo Nordisk Inc $10.0604/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810989211 CMS
Optinose US, Inc. $12.1704/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851647307 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.5304/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850271387 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $0.5904/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850418007 CMS
Novo Nordisk Inc $2.6004/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810805879 CMS
RedHill Biopharma Inc. $13.9904/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799932117 CMS
Antares Pharma, Inc. $16.1003/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827482523 CMS
PFIZER INC. $19.6903/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833566343 CMS
Nestle HealthCare Nutrition Inc. $19.5303/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820925831 CMS
Amarin Pharma Inc. $15.9503/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815387671 CMS
Biogen, Inc. $13.4503/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827773937 CMS
Astellas Pharma US Inc $15.3303/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821435937 CMS
AbbVie Inc. $12.7403/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795486757 CMS
AbbVie Inc. $4.3803/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795486763 CMS
Novo Nordisk Inc $7.6903/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811624611 CMS
Biohaven Pharmaceuticals, Inc. $14.3003/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852558319 CMS
Lilly USA, LLC $11.2303/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818580627 CMS
Corcept Therapeutics $15.7103/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837522331 CMS
Novo Nordisk Inc $6.7903/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810805873 CMS
Teva Pharmaceuticals USA, Inc. $15.8603/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839638553 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $4.7803/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850002547 CMS
Nestle HealthCare Nutrition Inc. $16.9602/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820925827 CMS
Novo Nordisk Inc $9.1002/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810805869 CMS
Astellas Pharma US Inc $79.9902/19/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821435931 CMS
AstraZeneca Pharmaceuticals LP $11.4102/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829852225 CMS
Amgen Inc. $14.5102/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825486847 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.7702/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850157175 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,499.97 160
PY2020 $1,550.12 121
PY2021 $3,553.03 169
PY2022 $2,689.53 178
PY2023 $2,881.30 189
PY2024 $2,443.95 150
PY2025 $1,742.00 110

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $706,819.70 54
PY2024 Principal investigator $806,998.27 34
PY2023 Recipient $500.00 1
PY2023 Principal investigator $975,438.32 27
PY2022 Recipient $958.00 1
PY2022 Principal investigator $615,185.50 14
PY2021 Principal investigator $195.16 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,114.08 12/31/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228815956
Principal investigator 1 Amgen Inc. $14,250.00 12/24/2025 Non-covered Recipient Entity
ALPINE RESEARCH TC LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246639077
Principal investigator 1 PFIZER INC. $4,614.72 12/17/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228816200
Principal investigator 1 PFIZER INC. $10,812.65 11/29/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228817382
Principal investigator 1 Janssen Research & Development, LLC $3,305.00 11/19/2025 Non-covered Recipient Entity
Alpine Rsrch Organization Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175292001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 11/07/2025 Non-covered Recipient Entity
Alpine Research Organization, Inc
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215509125
Principal investigator 1 Janssen Research & Development, LLC $6,433.00 11/07/2025 Non-covered Recipient Entity
Alpine Rsrch Organization Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175291961
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,700.00 11/05/2025 Non-covered Recipient Entity
Alpine Research Organization, Inc
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215509118
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,598.00 11/05/2025 Non-covered Recipient Entity
Alpine Research Organization, Inc
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215509121
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,700.00 11/05/2025 Non-covered Recipient Entity
ALPINE RESEARCH TC
Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185553385
Principal investigator 1 PFIZER INC. $1,694.88 11/04/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228817377
Principal investigator 1 Janssen Research & Development, LLC $264.00 11/03/2025 Non-covered Recipient Entity
Alpine Rsrch Organization Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175291938
Principal investigator 1 PFIZER INC. $16,027.18 10/31/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228824654
Principal investigator 1 Janssen Research & Development, LLC $12,467.00 10/22/2025 Non-covered Recipient Entity
Alpine Rsrch Organization Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175291969
Principal investigator 1 TOLMAR, INC. $2,540.41 10/16/2025 Non-covered Recipient Entity
ALPINE RESEARCH ORGANIZATION INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323085
Principal investigator 1 PFIZER INC. $16,638.07 10/15/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228826098
Principal investigator 1 PFIZER INC. $3,653.50 09/24/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228829604
Principal investigator 1 TOLMAR, INC. $2,540.41 09/23/2025 Non-covered Recipient Entity
ALPINE RESEARCH ORGANIZATION INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323011
Principal investigator 1 Janssen Research & Development, LLC $1,480.00 09/19/2025 Non-covered Recipient Entity
Alpine Rsrch Organization Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175291995
Principal investigator 1 PFIZER INC. $5,751.50 09/09/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228829598
Principal investigator 1 Janssen Research & Development, LLC $1,050.00 08/25/2025 Non-covered Recipient Entity
Alpine Rsrch Organization Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175291932
Principal investigator 1 Lumos Diagnostics, Inc. $6,300.00 08/06/2025 Non-covered Recipient Entity
Alpine Research Organization
CLP 0019 FebriDx Method Comparison Study Protocol No dispute reported 06/30/2026 1244033237
Principal investigator 1 PFIZER INC. $2,360.16 08/05/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228828326
Principal investigator 1 Janssen Research & Development, LLC $9,064.00 07/23/2025 Non-covered Recipient Entity
Alpine Rsrch Organization Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175291954
Principal investigator 1 PFIZER INC. $2,529.12 07/11/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228830253
Principal investigator 1 PFIZER INC. $1,272.48 06/26/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228829995
Principal investigator 1 Janssen Research & Development, LLC $1,578.00 06/23/2025 Non-covered Recipient Entity
Alpine Rsrch Organization Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175292019
Principal investigator 1 Janssen Research & Development, LLC $25,866.00 06/20/2025 Non-covered Recipient Entity
Alpine Rsrch Organization Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175291945
Principal investigator 1 TOLMAR, INC. $1,177.94 06/12/2025 Non-covered Recipient Entity
ALPINE RESEARCH ORGANIZATION INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237322886
Principal investigator 1 ModernaTX, Inc. $22,055.05 06/02/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252979726
Principal investigator 1 ModernaTX, Inc. $16,726.50 06/02/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252979730
Principal investigator 1 ModernaTX, Inc. $15,925.00 06/02/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252979734
Principal investigator 1 ModernaTX, Inc. $39,056.30 06/02/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252979736
Principal investigator 1 PFIZER INC. $1,628.35 05/30/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228832163
Principal investigator 1 PFIZER INC. $8,090.28 05/23/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228832156
Principal investigator 1 TOLMAR, INC. $3,000.00 05/15/2025 Non-covered Recipient Entity
ALPINE RESEARCH ORGANIZATION INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237322865
Principal investigator 1 TOLMAR, INC. $577.00 05/15/2025 Non-covered Recipient Entity
ALPINE RESEARCH ORGANIZATION INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237322870
Principal investigator 1 TOLMAR, INC. $1,580.00 05/15/2025 Non-covered Recipient Entity
ALPINE RESEARCH ORGANIZATION INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237322874
Principal investigator 1 TOLMAR, INC. $6,020.00 05/15/2025 Non-covered Recipient Entity
ALPINE RESEARCH ORGANIZATION INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237322877
Principal investigator 1 TOLMAR, INC. $853.86 05/15/2025 Non-covered Recipient Entity
ALPINE RESEARCH ORGANIZATION INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237322881
Principal investigator 1 PFIZER INC. $8,283.53 05/06/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228832054
Principal investigator 1 Janssen Research & Development, LLC $4,019.00 04/23/2025 Non-covered Recipient Entity
Alpine Rsrch Organization Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175291987
Principal investigator 1 TOLMAR, INC. $4,543.50 04/15/2025 Non-covered Recipient Entity
ALPINE RESEARCH ORGANIZATION INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237322863
Principal investigator 1 PFIZER INC. $514.27 04/08/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228832049
Principal investigator 1 TOLMAR, INC. $787.32 04/01/2025 Non-covered Recipient Entity
ALPINE RESEARCH ORGANIZATION INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237322855
Principal investigator 1 TOLMAR, INC. $1,059.70 04/01/2025 Non-covered Recipient Entity
ALPINE RESEARCH ORGANIZATION INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237322858
Principal investigator 1 PFIZER INC. $7,011.05 03/22/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228833256
Principal investigator 1 ModernaTX, Inc. $270.00 02/21/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252979732
Principal investigator 1 PFIZER INC. $10,065.00 02/06/2025 Non-covered Recipient Entity
Alpine Research Organization
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228829021
Principal investigator 1 Eli Lilly and Company $7,530.89 01/27/2025 Non-covered Recipient Entity
UTAH CARDIOLOGY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187892598
Principal investigator 1 Eli Lilly and Company $84,150.00 01/21/2025 Non-covered Recipient Entity
UTAH CARDIOLOGY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187892596
Principal investigator 1 ModernaTX, Inc. $1,500.00 01/17/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252979724
Principal investigator 1 ModernaTX, Inc. $400.00 01/17/2025 Non-covered Recipient Entity
PHARMASEEK LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252979728
Principal investigator 1 Eli Lilly and Company $279,391.00 01/07/2025 Non-covered Recipient Entity
UTAH CARDIOLOGY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187890610